查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1656921

原位杂交市场：全球洞察、竞争格局与 2032 年预测

In Situ Hybridization - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

到 2024 年，原位杂交市场规模预计将达到 16.7355 亿美元。预计预测期内（2025-2032 年），市场复合年增长率为 7.12%，到 2032 年将达到 28.8613 亿美元。原位杂交的需求大幅增加，主要原因是癌症和遗传疾病的发生率不断上升。此外，神经疾病和传染病的趋势也进一步推动了这项需求。除此之外，研发活动和资金的增加是推动原位杂交市场成长轨迹的关键因素。预计这一成长趋势将在 2025 年至 2032 年的整个预测期内持续并蓬勃发展。

ISH 用于诊断唐氏症和爱德华氏症等先天性疾病。研究可以分析特定基因在组织和器官中的表现方式，阐明它们在发育过程、疾病和生理功能中的作用。因此，患有遗传疾病和一些罕见疾病的人数不断增加，预计将促进市场的成长。例如，根据世界经济论坛2023年2月发布的报告，2019年约有4.75亿人患有罕见疾病，占世界人口的10%。未来五年内，预计约有 1,520 万人将接受专为识别罕见疾病而设计的临床基因组检测。

根据强生公司2023年2月发表的文章估计，截至2023年，全球将有超过3亿人患有罕见疾病。萤光原位杂交（FISH）是病理学家用来帮助诊断染色体异常引起的疾病的基因检测技术。因此，遗传疾病和罕见疾病的增加促进了原位杂交的广泛应用，预计这将推动市场成长。

根据世界卫生组织（WHO）2022年发布的数据，2020年全球报告乳癌约226万例、肺癌221万例、大肠直肠癌193万例、摄护腺癌141万例、胃癌109万例。

根据全球癌症观察站2021年发表的数据，2020年全球报告了约544,352例非何杰金氏淋巴瘤和83,087例霍奇金淋巴瘤。据同一消息来源称，2020 年全球报告了约 474,519 例白血病病例和约 176,404 例多发性骨髓瘤病例。原位杂交是研究癌症相关基因表现变化和染色体异常的有价值的工具，有助于发现潜在的诊断指标和治疗干预目标，从而推动市场成长。

爱滋病毒和肝炎等传染病的增加也是原位杂交 (ISH) 市场的主要驱动力。原位杂交 (ISH) 结合实验室医学和分子遗传技术来检测传染性病原体。萤光原位杂交 (FISH) 特别适用于在保持细胞结构完整性的同时识别和定位不同样本中的核甘酸序列。根据2022年世界卫生组织（WHO）的公告，预计2022年全球将有约3.54亿人感染B型肝炎或C型肝炎。

政府的支持和资助旨在最大限度地发挥罕见疾病伙伴关係的价值，其总体目标是提高罕见疾病领域的研究和创新水平。例如，2023 年 9 月，英国研究和创新部门将总投资约 7.985 亿美元（6.27 亿英镑），涵盖一系列旨在推进罕见疾病研究的措施。值得注意的是，2016 年至 2021 年期间，MRC 奖学金和 NIHR 职业发展奖已获得 1.269 亿美元（9,970 万英镑）的拨款，展现了围绕罕见疾病研究工作的全面支持网络。

本报告概述了全球原位杂交市场，包括按产品类型、技术、应用、最终用户、区域趋势和公司概况划分的市场概述。

目录

第 1 章 原位杂交市场报告简介

第 2 章 原位杂化市场执行摘要

第3章 竞争格局

第 4 章 监理分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第五章 原位杂交市场关键因素分析

  • 原位杂交市场推动因素
  • 原位杂交市场的限制与课题
  • 原位杂交市场机会

第 6 章 原位杂交市场的波特五力分析

第 7 章 原位杂交市场评估

  • 依产品类型
    • 设备
    • 试剂和试剂盒
    • 软体
  • 按技术
    • 萤光原位杂交（FISH）
    • 显色原位杂交 (CISH)
    • 其他
  • 依用途
    • 癌症诊断
    • 遗传性疾病
    • 传染病
  • 按最终用户
    • 医院和诊所
    • 诊断中心
    • 製药和生技公司
    • 学术和政府机构
  • 按地区
    • 北美洲
    • 欧洲 亚太地区
    • 其他地区
第 8 章：原位杂化市场公司与产品概况
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • PerkinElmer Inc.
  • Sysmex Corporation
  • Biocare Medical, LLC
  • Genemed Biotechnologies, Inc.
  • NeoGenomics Laboratories
  • Advanced Cell Diagnostics, Inc.
  • BioView
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • QIAGEN
  • BioGenex
  • ZYTOVISION GmbH
  • Promega Corporation
  • Illumina, Inc.
  • Danaher Corporation

第 9 章 KOL 视角

第 10 章 专案方法

第 11 章 关于 DelveInsight

第12章 免责声明及联络我们

Product Code: DISR0209

In Situ Hybridization Market by Product Type (Instruments, Reagents & Kits, and Software), Technology (Fluorescence In Situ Hybridization (FISH), Chromogenic In Situ Hybridization (CISH), and Others), Application (Cancer Diagnosis, Genetic Diseases, Infectious Diseases, and Others), End-User (Hospitals and Clinics, Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of cancer and genetic diseases and increasing incidences of neurological disorders and infectious disease

The in situ hybridization market was valued at USD 1,673.55 million in 2024, growing at a CAGR of 7.12% during the forecast period from 2025 to 2032 to reach USD 2,886.13 million by 2032. The demand for in situ hybridization is witnessing a notable surge, driven predominantly by the escalating prevalence of cancer and genetic diseases. Additionally, the upward trend in neurological disorders and infectious diseases further fuels this demand. Coupled with this, the intensifying R&D activities and funding are pivotal factors propelling the positive growth trajectory of the in situ hybridization market. This growth trend is expected to persist and flourish throughout the forecast period spanning from 2025 to 2032.

In Situ Hybridization Market Dynamics:

ISH is used to diagnose congenital diseases such as Down's syndrome and Edward's Syndrome. It enables researchers to analyze how certain genes are expressed in tissues or organs, shedding light on their involvement in developmental processes, diseases, and physiological functions. Therefore, the rising number of people affected by genetic or some kind of rare disease is expected to contribute to the growth of the market. For instance, a report by the World Economic Forum in February 2023, stated that approximately 475 million individuals were suffering from rare conditions in 2019 which comprised 10% of the global population. Within the upcoming five years, it was anticipated that around 15.2 million people were expected to undergo clinical genomic testing specifically aimed at identifying rare conditions.

According to an article shared by Johnson & Johnson in February 2023, the estimate suggests that over 300 million individuals were affected with rare diseases as of 2023 globally. Fluorescence in situ hybridization (FISH) is a genetic testing technique used by pathologists to aid in diagnosing diseases attributed to chromosomal abnormalities. Therefore, the growing genetic and rare diseases contribute to the extensive use of in situ hybridization which is expected to drive the market growth.

According to data cited by the World Health Organization in 2022, around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020 around the world.

As per data published by Global Cancer Observatory in 2021, around 544,352 cases of non-Hodgkin lymphoma and 83,087 cases of Hodgkin lymphoma were reported in 2020 worldwide. As per the same source, around 474,519 leukemia cases and nearly 176,404 cases of multiple myeloma were reported in 2020 across the globe. In situ hybridization serves as a valuable tool in examining changes in gene expression or chromosomal irregularities linked to cancer, aiding in the discovery of potential diagnostic indicators and targets for therapeutic intervention, thereby driving market growth.

The rising cases of infectious diseases such as HIV, hepatitis, and others is another key driver for the in situ hybridization (ISH) market. In situ hybridization (ISH) amalgamates laboratory medicine with molecular genetics technology to detect infectious pathogens. Fluorescence in situ hybridization (FISH) specifically aids in identifying and pinpointing nucleotide sequences within diverse samples, all while maintaining the integrity of cellular structures. According to the World Health Organization (WHO) 2022, it was estimated that around 354 million people were living with Hepatitis B or C infections in 2022 globally.

Government support and funding are directed towards maximizing the value derived from the Rare Diseases Partnership, with the overarching goal of fostering increased levels of research and innovation in the field of rare diseases. For instance, in September 2023, UK Research and Innovation, the investment, totaling nearly USD 798.5 million (GBP 627 million), encompasses various initiatives aimed at advancing rare disease research. Notably, USD 126.9 million (GBP 99.7 million) had been allocated to MRC fellowships and NIHR career development awards between 2016 and 2021, illustrating the comprehensive support network surrounding rare disease research efforts.

However, the in situ hybridization market may face growth constraints due to various factors, including the inefficiency of detecting DNA level rearrangements and chromosome pairs and concerns regarding potential exposure to radioactivity.

In Situ Hybridization Market Segment Analysis:

In Situ Hybridization Market by Product Type (Instruments, Reagents & Kits, and Software), Technology (Fluorescence In Situ Hybridization (FISH), Chromogenic In Situ Hybridization (CISH), and Others), Application (Cancer Diagnosis, Genetic Diseases, Infectious Diseases, and Others), End-User (Hospitals and Clinics, Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the technology segment of the in situ hybridization market, the fluorescence in situ hybridization (FISH) category is estimated to account for a significant revenue share in the in situ hybridization market in 2024. This is attributed to the growing use of FISH in cancer diagnosis and research. In oncology, FISH is utilized to identify genetic changes linked with cancer, including gene amplifications, deletions, and rearrangements of chromosomes. Fluorescence in situ hybridization (FISH) is mainly used in the diagnosis, categorization, prognosis, and anticipation of treatment outcomes in cancer patients.

The application of FISH spans a broad spectrum of scientific disciplines, including genetic counseling, subcellular studies, detection and localization of chromosome mutations, species identification, biomedical research, clinical diagnosis, toxicology, chromosomal biology, and comparative genomics.

Key players in the market are developing innovative kits and reagents for fluorescence in situ hybridization (FISH) procedures. For instance, in December 2021, BioGenex, a US-based molecular pathology company launched NanoVIP. NanoVIP is a compact, fully automated bench-top system equipped with visualization kits designed for fluorescence in situ hybridization (FISH) and in-situ hybridization (ISH). Its 10-slide design ensures reliability through automation, featuring eXACT(TM) temperature control modules for individual slide positions, precise management of reaction times, and liquid level sensors for accurate liquid handling. This meticulous control ensures the delivery of clean, intense, reliable, and reproducible stains, minimizing the need for repeat procedures.

Further, in cellular biology and neuroscience, scientists utilize techniques such as fluorescence in situ hybridization (FISH) to investigate the expression, localization, and dynamics of genes within cells and tissues. This method allows for the visualization of specific genes or RNA molecules in various cell types including neuronal cells, glial cells, and others. By studying gene expression patterns and their spatial distribution, researchers gain valuable insights into brain function, development, and the underlying mechanisms of neurological disorders. Additionally, FISH can aid in the diagnosis of genetic disorders by enabling the visualization of specific chromosomal regions or genes associated with these conditions. Therefore, the wide applications of the fluorescence in situ hybridization (FISH) category is expected to contribute to the growth of the segment, thereby driving the growth of the in situ hybridization market during the forecast period.

North America is expected to dominate the Overall In-Situ Hybridization Market:

North America is estimated to dominate the in situ hybridization market in 2024. This is attributed to the growing prevalence of cancer and rare genetic diseases. In situ hybridization (ISH) stands as a pivotal tool in cancer research and diagnosis, facilitating the detection of gene expression and genetic abnormalities linked with cancer. These capabilities significantly contribute to the growth of the market in the region. Moreover, the escalating number of molecular diagnostics tests conducted in the region further propels the expansion of the North America in situ hybridization market.

Fluorescence in situ hybridization (FISH) is a diagnostic test that maps the genetic material within human cells, pinpointing specific genes or gene segments. Due to its capability to detect genetic abnormalities linked to cancer, FISH serves as a valuable tool in diagnosing certain types of the disease. For instance, according to the National Cancer Institute 2020, it was estimated that around 1,806,590 cancer cases were diagnosed in the year 2020 in the United States.

According to the Centers for Disease Control and Prevention (CDC) in May 2024, approximately 5,700 babies were born with Down syndrome each year in the United States. This equates to a prevalence of about 1 in every 640 babies. In situ hybridization is used to identify an extra chromosome or an extra piece of a chromosome for diagnosis of Down syndrome. Therefore, the growing prevalence of rare and genetic diseases is expected to drive the market growth in the region.

In Situ Hybridization Market Key Players:

Some of the key market players operating in the in situ hybridization market include Abbott Laboratories, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., PerkinElmer Inc., Sysmex Corporation, Biocare Medical, LLC, Genemed Biotechnologies, Inc., NeoGenomics Laboratories, Advanced Cell Diagnostics, Inc., BioView, Bio-Rad Laboratories, Inc., Bio-Techne, QIAGEN, BioGenex, ZYTOVISION GmbH, Promega Corporation, Illumina, Inc., Danaher Corporation, and others.

Recent Developmental Activities in the In-Situ Hybridization Market:

  • In January 2024, Biocare Medical, LLC, a US-based tissue diagnostic company announced its collaboration with Molecular Instruments to develop automated bioimaging. This partnership combines Biocare Medical's proficiency in automated bioimaging systems with MI's array of advanced HCR(TM) Products, establishing a new benchmark in automated in situ hybridization (ISH) and immunohistochemistry (IHC).
  • In May 2023, Bio-Techne, a US-based life sciences company launched Advanced Cell Diagnostics (ACD)-branded RNAscope(TM) in situ hybridization (ISH). RNAscope HiPlex12 Flex Kit allows for the visualization of highly multiplexed RNA biomarkers utilizing the Hyperion XTi or previous versions of the Hyperion Imaging System. This cutting-edge system facilitates the simultaneous detection and precise quantification of over 40 biomarkers from any tissue sample in a single imaging step, employing Imaging Mass Cytometry.
  • In November 2022, Biocare Medical, LLC completed the acquisition of Empire Genomics, a molecular biomarkers company pioneering in cancer research and diagnostics. This acquisition serves to complement our extensive portfolio of IHC antibodies, comprehensive molecular menu, and sophisticated automation platform.
  • In January 2022, Bio-Techne announced its partnership with Akoya Biosciences, Inc. to develop a single-cell, spatial multiomics workflow for comprehensive, unbiased analysis of tissue samples. Through this agreement, both companies worked to develop an automated spatial multiomics workflow capable of conducting rapid, in situ analysis of multiple analytes at single-cell resolution across entire slides.

Key Takeaways from the In Situ Hybridization Market Report Study

  • Market size analysis for current In Situ Hybridization Market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the global In Situ Hybridization market.
  • Various opportunities available for the other competitors in the In Situ Hybridization Market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current In Situ Hybridization market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for In Situ Hybridization market growth in the coming future?

TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS IN SITU HYBRIDIZATION MARKET REPORT STUDY

  • In Situ Hybridization product providers
  • Research organizations and consulting companies
  • In Situ Hybridization related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in In Situ Hybridization
  • Various end-users who want to know more about the In Situ Hybridization Market and the latest technological developments in the In Situ Hybridization Market.

FREQUENTLY ASKED QUESTIONS FOR THE IN SITU HYBRIDIZATION MARKET:

1. What is In Situ Hybridization?

  • In situ hybridization (ISH) is a method in molecular biology utilized to identify and pinpoint specific nucleic acid sequences within fixed tissues, cells, or organisms. It involves pairing a labelled nucleic acid probe, complementary to the target sequence, with the sample. This probe, often tagged with a fluorescent dye, radioactive label, or another identifiable marker, binds to its complementary sequence in the sample. Following hybridization, the location of the probe within the sample is observed using microscopy or autoradiography, offering insights into the spatial arrangement of RNA or DNA molecules and facilitating the examination of gene expression patterns, chromosomal structure, and cellular interactions.

2. What is the market for In Situ Hybridization?

  • The in situ hybridization market was valued at USD 1,673.55 million in 2024, growing at a CAGR of 7.12% during the forecast period from 2025 to 2032 to reach USD 2,886.13 million by 2032.

3. What are the drivers for the In Situ Hybridization market?

  • The in situ hybridization market is slated to witness prosperity owing to factors such as the escalating prevalence of cancer and genetic diseases. Additionally, the upward trend in neurological disorders and infectious diseases further fuels this demand. Coupled with this, the intensifying R&D activities and funding are pivotal factors propelling the positive growth trajectory of the in situ hybridization market. This growth trend is expected to persist and flourish throughout the forecast period spanning from 2025 to 2032.

4. Who are the key players operating in the In Situ Hybridization market?)

  • Some of the key market players operating in the in situ hybridization market include Abbott Laboratories, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., PerkinElmer Inc., Sysmex Corporation, Biocare Medical, LLC, Genemed Biotechnologies, Inc., NeoGenomics Laboratories, Advanced Cell Diagnostics, Inc., BioView, Bio-Rad Laboratories, Inc., Bio-Techne, QIAGEN, BioGenex, ZYTOVISION GmbH, Promega Corporation, Illumina, Inc., Danaher Corporation, and others.

5. Which region has the highest share in the In Situ Hybridization market?

  • North America is estimated to dominate in the in situ hybridization market in 2024. This is attributed to the growing prevalence of cancer and rare genetic diseases. In situ hybridization (ISH) stands as a pivotal tool in cancer research and diagnosis, facilitating the detection of gene expression and genetic abnormalities linked with cancer. These capabilities significantly contribute to the growth of the market in the region. Moreover, the escalating number of molecular diagnostics tests conducted in the area further propels the expansion of the North America in situ hybridization market.

Table of Contents

1. In Situ Hybridization Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. In Situ Hybridization Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. In Situ Hybridization Market Key Factors Analysis

  • 5.1. In Situ Hybridization Market Drivers
    • 5.1.1. The escalating prevalence of cancer and genetic diseases.
    • 5.1.2. The upward trend in neurological disorders and infectious diseases
    • 5.1.3. The intensifying R&D activities and funding
  • 5.2. In Situ Hybridization Market Restraints and Challenges
    • 5.2.1. High cost associated with in situ hybridization assays
    • 5.2.2. Concerns regarding potential exposure to radioactivity
  • 5.3. In Situ Hybridization Market Opportunity
    • 5.3.1. Focus towards automation in in situ hybridization (ISH)
    • 5.3.2. Integration of artificial intelligence and deep learning in diagnostics

6. In Situ Hybridization Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. In Situ Hybridization Market Assessment

  • 7.1. By Product Type
    • 7.1.1. Instruments
    • 7.1.2. Reagents and Kits
    • 7.1.3. Software
  • 7.2. By Technology
    • 7.2.1. Fluorescence In Situ Hybridization (FISH)
    • 7.2.2. Chromogenic In Situ Hybridization (CISH)
    • 7.2.3. Others
  • 7.3. By Application
    • 7.3.1. Cancer Diagnosis
    • 7.3.2. Genetic Diseases
    • 7.3.3. Infectious Diseases
    • 7.3.4. Others
  • 7.4. By End-User
    • 7.4.1. Hospitals and Clinics
    • 7.4.2. Diagnostic Centers
    • 7.4.3. Pharmaceutical And Biotechnology Companies
    • 7.4.4. Academic and Government Institutes
    • 7.4.5. Others
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.1.2. Canada In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.1.3. Mexico In Situ Hybridization Market Size in USD million (2022-2032)
    • 7.5.2. Europe
      • 7.5.2.1. France In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.2.2. Germany In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.2.3. United Kingdom In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.2.4. Italy In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.2.5. Spain In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.2.6. Rest of Europe In Situ Hybridization Market Size in USD million (2022-2032)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.3.2. Japan In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.3.3. India In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.3.4. Australia In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.3.5. South Korea In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.3.6. Rest of Asia-Pacific In Situ Hybridization Market Size in USD million (2022-2032)
    • 7.5.4. Rest of the World (RoW)
      • 7.5.4.1. Middle East In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.4.2. Africa In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.4.3. South America In Situ Hybridization Market Size In USD Million (2022-2032)

8. In Situ Hybridization Market Company and Product Profiles

  • 8.1. Abbott Laboratories
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Agilent Technologies, Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Thermo Fisher Scientific Inc.
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. F. Hoffmann-La Roche Ltd
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Merck & Co., Inc.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. PerkinElmer Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Sysmex Corporation
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Biocare Medical, LLC
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Genemed Biotechnologies, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. NeoGenomics Laboratories
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Advanced Cell Diagnostics, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. BioView
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Bio-Rad Laboratories, Inc.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Bio-Techne
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. QIAGEN
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. BioGenex
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. ZYTOVISION GmbH
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Promega Corporation
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Illumina, Inc.
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Danaher Corporation
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: In Situ Hybridization Market in Global (2022-2032)
  • Table 3: In Situ Hybridization Market in Global by Product Type (2022-2032)
  • Table 4: In Situ Hybridization Market in Global by Technology (2022-2032)
  • Table 5: In Situ Hybridization Market in Global by Application (2022-2032)
  • Table 6: In Situ Hybridization Market in Global by End-User (2022-2032)
  • Table 7: In Situ Hybridization Market in Global by Geography (2022-2032)
  • Table 8: In Situ Hybridization Market in North America (2022-2032)
  • Table 9: In Situ Hybridization Market in the US (2022-2032)
  • Table 10: In Situ Hybridization Market in Canada (2022-2032)
  • Table 11: In Situ Hybridization Market in Mexico (2022-2032)
  • Table 12: In Situ Hybridization Market in Europe (2022-2032)
  • Table 13: In Situ Hybridization Market in France (2022-2032)
  • Table 14: In Situ Hybridization Market in Germany (2022-2032)
  • Table 15: In Situ Hybridization Market in the United Kingdom (2022-2032)
  • Table 16: In Situ Hybridization Market in Italy (2022-2032)
  • Table 17: In Situ Hybridization Market in Spain (2022-2032)
  • Table 18: In Situ Hybridization Market in Rest of Europe (2022-2032)
  • Table 19: In Situ Hybridization Market in Asia-Pacific (2022-2032)
  • Table 20: In Situ Hybridization Market in China (2022-2032)
  • Table 21: In Situ Hybridization Market in Japan (2022-2032)
  • Table 22: In Situ Hybridization Market in India (2022-2032)
  • Table 23: In Situ Hybridization Market in Australia (2022-2032)
  • Table 24: In Situ Hybridization Market in South Korea (2022-2032)
  • Table 25: In Situ Hybridization Market in Rest of Asia-Pacific (2022-2032)
  • Table 26: In Situ Hybridization Market in Rest of the World (2022-2032)
  • Table 27: In Situ Hybridization Market in the Middle East (2022-2032)
  • Table 28: In Situ Hybridization Market in Africa (2022-2032)
  • Table 29: In Situ Hybridization Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: In Situ Hybridization Market in Global (2022-2032)
  • Figure 3: In Situ Hybridization Market in Global by Product Type (2022-2032)
  • Figure 4: In Situ Hybridization Market in Global by Technology (2022-2032)
  • Figure 5: In Situ Hybridization Market in Global by Application (2022-2032)
  • Figure 6: In Situ Hybridization Market in Global by End-User (2022-2032)
  • Figure 7: In Situ Hybridization Market in Global by Geography (2022-2032)
  • Figure 8: In Situ Hybridization Market in North America (2022-2032)
  • Figure 9: In Situ Hybridization Market in the US (2022-2032)
  • Figure 10: In Situ Hybridization Market in Canada (2022-2032)
  • Figure 11: In Situ Hybridization Market in Mexico (2022-2032)
  • Figure 12: In Situ Hybridization Market in Europe (2022-2032)
  • Figure 13: In Situ Hybridization Market in France (2022-2032)
  • Figure 14: In Situ Hybridization Market in Germany (2022-2032)
  • Figure 15: In Situ Hybridization Market in the United Kingdom (2022-2032)
  • Figure 16: In Situ Hybridization Market in Italy (2022-2032)
  • Figure 17: In Situ Hybridization Market in Spain (2022-2032)
  • Figure 18: In Situ Hybridization Market in Rest of Europe (2022-2032)
  • Figure 19: In Situ Hybridization Market in Asia-Pacific (2022-2032)
  • Figure 20: In Situ Hybridization Market in China (2022-2032)
  • Figure 21: In Situ Hybridization Market in Japan (2022-2032)
  • Figure 22: In Situ Hybridization Market in India (2022-2032)
  • Figure 23: In Situ Hybridization Market in Australia (2022-2032)
  • Figure 24: In Situ Hybridization Market in South Korea (2022-2032)
  • Figure 25: In Situ Hybridization Market in Rest of Asia-Pacific (2022-2032)
  • Figure 26: In Situ Hybridization Market in Rest of the World (2022-2032)
  • Figure 27: In Situ Hybridization Market in the Middle East (2022-2032)
  • Figure 28: In Situ Hybridization Market in Africa (2022-2032)
  • Figure 29: In Situ Hybridization Market in South America (2022-2032)
  • Figure 30: Market Drivers
  • Figure 31: Market Barriers
  • Figure 32: Marker Opportunities
  • Figure 33: PORTER'S Five Force Analysis